Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming trial, EBRX-101 is designed to be one of the most comprehensive studies of DMT to date and will evaluate the pharmacodynamics, pharmacokinetics, and safety profile of DMT to advance it as a therapy for addiction disorder. In…